“Moving towards equitable access to vaccination.”
The Serum Institute vaccine is designed to protect children in low-resource countries from the kinds of pneumococcus that cause the most disease where they live at less than two-thirds of the usual cost.
The vaccine was developed by Serum Institute and PATH through a collaboration originating in 2008 and with funding contributed by the Bill & Melinda Gates Foundation.
Description:Individual conjugates are compounded and then polysorbate 20 and aluminium phosphate are added to formulate the vaccine.
Composition:Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) (10-valent) 0.5 ml – 1 dose
Each dose of 0.5 ml contains:Saccharide for serotypes 1, 5, 9V, 14, 19A, 19F, 23F, 7F, 6A – 2 mcg each Saccharide for serotype 6B – 4 mcg
Conjugated to CRM197 carrier protein Aluminium (as Aluminium phosphate) 0.125 mg
Dose:0.5 ml by intramuscular injection